Utilization of varenicline among Kansas Medicaid enrollees
PLOS One · 2025
DOI: 10.1371/journal.pone.0333723 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nathalia M Machado und 3 weiteren Autor:innen. Beteiligte Einrichtung: TSET Health Promotion Research Center, Stephenson Cancer Center, The University of Oklahoma Health Campus, Oklahoma City, Oklahoma, United States of …. Hauptthemen laut MEDLINE: Varenicline, Medicaid, Smoking Cessation, Smoking Cessation Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, American Association of University Women.
Abstract (Originalsprache)
Background
Smoking prevalence among Medicaid beneficiaries is twice that of privately insured adults, yet effective smoking cessation treatments remain underutilized. Understanding varenicline use, the most effective smoking cessation medication, can inform efforts to improve tobacco treatment for Medicaid enrollees.
Objectives
To describe varenicline utilization among Kansas Medicaid (KanCare) enrollees from 2014–2021, including changes related to the FDA’s December 2016 removal of the black box warning, and explore changes and demographic differences in its use. Research design This retrospective cohort study analyzed pharmacy claims data for varenicline utilization from January 1, 2014, to December 31, 2021. Tobacco use was estimated from the KanCare External Quality Review survey. Subjects The sample included 78,295 new adult enrollees (age 18+) with at least 11 months of continuous coverage. Measures The primary outcome was varenicline utilization, defined as any pharmacy claim for the medication. Secondary outcomes included time to first prescription, completion of the 12-week treatment, and demographic differences in use.
Results
With an estimated 30% smoking prevalence, only 12.7% of KanCare smokers received varenicline, and just 1.6% completed a full course of treatment. Among 78,295 new enrollees, 2,980 (3.8%) had one or more claims for varenicline, with the mean time from enrollment to first prescription being 1.5 years (SD 1.3). Utilization was higher among males (4.8%) than females (3.4%) and varied by race/ethnicity (Whites: 4.4%, Blacks: 2.7%, American Indians: 2.5%, Hispanics: 1.6%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TSET Health Promotion Research Center, Stephenson Cancer Center, The University of Oklahoma Health Campus, Oklahoma City, Oklahoma, United States of America.
- Department of Population Heath, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
ORCID-Profile: Nathalia M Machado
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- American Association of University Women
Zitieren
APA
Machado, N. M., Katz, A. J., Richter, K. P., & Ellerbeck, E. F. (2025). Utilization of varenicline among Kansas Medicaid enrollees. PLOS One. https://doi.org/10.1371/journal.pone.0333723
Vancouver
Machado NM, Katz AJ, Richter KP, Ellerbeck EF. Utilization of varenicline among Kansas Medicaid enrollees. PLOS One. 2025. doi:10.1371/journal.pone.0333723
BibTeX
@article{Machado2025,
author = {Machado, Nathalia M and Katz, Aaron J and Richter, Kimber P and Ellerbeck, Edward F},
title = {Utilization of varenicline among Kansas Medicaid enrollees},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333723}
}
EUVIMED